Platelet alpha granule growth factor release

Platelet alpha granule growth factor release is a physiological process involving the regulated exocytosis of alpha-granules, the most abundant secretory organelles in platelets (Blair & Flaumenhaft, 2009, Blood Reviews). These granules house a diverse cargo of bioactive proteins, including growth factors such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-beta), and Vascular Endothelial Growth Factor (VEGF), which are essential for wound healing and vascular repair (Golebiewska & Poole, 2015, Blood Reviews). The release is initiated by platelet activation through agonists like thrombin, collagen, or ADP, which trigger intracellular signaling and the subsequent fusion of granule membranes with the plasma membrane via SNARE proteins (Heijnen & Lagerweij, 2017, Platelets). While vital for normal hemostasis, the excessive release of these factors contributes to the pathogenesis of arterial thrombosis, atherosclerosis, and the promotion of a pro-tumorigenic microenvironment in cancer (Coppinger et al., 2004, Blood). Pharmacological modulation of this process is typically achieved indirectly through antiplatelet drugs, such as P2Y12 receptor antagonists (e.g., Clopidogrel) or COX-1 inhibitors (e.g., Aspirin), which reduce the overall activation state of the platelet and thereby limit the secretion of granule contents (Angiolillo et al., 2017, JACC). Consequently, this entry represents a functional biological process or phenotypic readout of platelet activity rather than a single molecular target entity.

Other names

Platelet alpha-granule secretionPlatelet degranulationRelease of platelet-derived growth factorsPlatelet secretory granule exocytosis

Inhibition of upstream platelet activation signaling pathways, such as P2Y12 receptor antagonism, COX-1 inhibition, or PAR-1 antagonism, to prevent the intracellular signaling cascades that trigger SNARE-mediated granule exocytosis.